LCB-03-0110

LCB-03-0110 is a **potent multi-tyrosine kinase inhibitor** developed as a small molecule drug targeting several key kinases, including Discoidin domain receptor 1 (DDR1), C-terminal Src kinase (CSK), Janus kinase (JAK), Signal transducer and activator of transcription 3 (STAT3), and Vascular endothelial growth factor receptor 2 (VEGFR2). It acts via **ATP-competitive inhibition** at the kinase active site, suppressing multiple pro-inflammatory and pro-angiogenic signaling pathways. LCB-03-0110 shows anti-inflammatory activity by significantly inhibiting phosphorylation of ERK and P38 and reducing expression of inflammatory cytokines (IL-6, IL-8, IL-17A), with efficacy demonstrated in models for dry eye disease, tumor angiogenesis, and neurodegenerative pathology. It additionally inhibits Tie2, BTK, SYK, FLT1, FLT3, FLT4, EphA3, EphB4, and c-Abl. Studies show benefits over tacrolimus and tofacitinib without cytotoxicity to tested cells, and promising anti-angiogenic and anti-metastatic effects in preclinical models[1][2][3][5].

Other names

LCB-03-0110LCB03-0110LCB 03-0110LCB-03-110LCB03-110LCB 03-110